Can-Fite BioPharma (CANF) Institutional Ownership $0.66 -0.01 (-0.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.66 0.00 (-0.15%) As of 08/22/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Can-Fite BioPharma (NYSE:CANF)CurrentInstitutional OwnershipPercentage21.00%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$90.78KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$16.53K Get CANF Insider Trade Alerts Want to know when executives and insiders are buying or selling Can-Fite BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CANF Institutional Buying and Selling by Quarter Can-Fite BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/29/2025 Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 4/8/2025 Rhumbline Advisers38,268$57K0.0%+42.4%1.081% 2/17/2025 BNP Paribas Financial Markets25,185$41K0.0%N/A0.711% 2/14/2025 Two Sigma Securities LLC19,395$32K0.0%-34.4%0.548% 1/30/2025 Rhumbline Advisers26,880$44K0.0%+58.6%0.759% 8/15/2024 Armistice Capital LLC518,853$1.34M0.0%+35.5%14.657% 2/13/2024 Armistice Capital LLC154,363$340K0.0%N/A4.361% 1/17/2024Schechter Investment Advisors LLC20,077$44K0.0%N/A0.567% 2/10/2022 Acadian Asset Management LLC28,601$36K0.0%-75.1%0.105% 11/16/2021Cetera Advisor Networks LLC130,776$217K0.0%-16.9%0.607% 10/15/2021 Fifth Third Bancorp30,000$50K0.0%N/A0.149% 8/6/2021 StoneX Group Inc.40,000$91K0.0%N/A0.233% (Data available from 1/1/2016 forward) CANF Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CANF shares? During the previous two years, the following institutional investors and hedge funds held shares of Can-Fite BioPharma shares: Armistice Capital LLC ($1.34M), Rhumbline Advisers ($57K), Schechter Investment Advisors LLC ($44K), and BNP Paribas Financial Markets ($41K), Two Sigma Securities LLC ($32K).Learn more on Can-Fite BioPharma's institutional investors. What percentage of Can-Fite BioPharma's stock is owned by institutional investors? 21.00% of Can-Fite BioPharma's stock is owned by institutional investors. Learn more on CANF's institutional investor holdings. Which institutional investors have been buying Can-Fite BioPharma's stock? The following institutional investors have purchased Can-Fite BioPharma's stock in the last 24 months: Armistice Capital LLC ($290.42K), Rhumbline Advisers ($32.71K), BNP Paribas Financial Markets ($25.19K), and Schechter Investment Advisors LLC ($20.08K). How much institutional buying is happening at Can-Fite BioPharma? Institutional investors have bought a total of 57,896 shares in the last 24 months. This purchase volume represents approximately $90.78K in transactions. Which of Can-Fite BioPharma's major shareholders have been selling company stock? The following institutional investors have sold Can-Fite BioPharma stock in the last 24 months: Two Sigma Securities LLC ($10.18K). How much institutional selling is happening at Can-Fite BioPharma? Institutional investors have sold a total of 10,175 shares in the last 24 months. This volume of shares sold represents approximately $16.53K in transactions. Related Companies Portage Biotech Major Shareholders Soligenix Major Shareholders TransCode Therapeutics Major Shareholders Sonoma Pharmaceuticals Major Shareholders Talphera Major Shareholders Adial Pharmaceuticals Major Shareholders AEON Biopharma Major Shareholders Addex Therapeutics Major Shareholders Turnstone Biologics Major Shareholders Acurx Pharmaceuticals Major Shareholders This page (NYSE:CANF) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access